ChulaCov19, mRNA vaccine, Thai nationality, submits to FDA, expects to register at the end of the year

via Chulalongkorn University Has reported the progress of the development of the Thai national covid vaccine “ChulaCov19” type mRNA. The first phase of development is the vaccine design and production in the United States factory. which was successfully tested in phase 1 and 2 subjects It is safer and can boost immunity than the Pfizer vaccine approved for use in Thailand.

The second phase is the domestic production of vaccines by Bionet Asia Co., Ltd., which has already produced the first lot of vaccines. and passed quality assurance